

# Magle Group publishes merger document regarding the merger with Amniotics

**Today, Magle Chemoswed Holding AB ("Magle Group" or the "Company") announces that the merger document regarding the merger (the "Merger") with Amniotics AB (publ) ("Amniotics") has been published on the companies' websites: [www.maglegroup.com](http://www.maglegroup.com) and [www.amniotics.com](http://www.amniotics.com). As previously announced, the Merger is expected to be completed on or about 3 October 2024.**

## **Advisors**

Vator Securities AB is financial advisor in connection with the Merger. Advokatfirman Schjødt is legal advisor to Magle Group in connection with the Merger.

## **For enquiries, please contact:**

### **Magle Group**

Justin Pierce, CEO

Email: [justin.pierce@maglechemoswed.com](mailto:justin.pierce@maglechemoswed.com)

Telephone: +46 (0)70 593 58 21

For administrative questions regarding the Merger, please contact your bank or the nominee registered as holder of your shares.

## **About us**

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on [www.maglechemoswed.com](http://www.maglechemoswed.com) and <https://maglegroup.com/> and [www.maglepharmaceut.com](http://www.maglepharmaceut.com).

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at [ca@vatorsec.se](mailto:ca@vatorsec.se) or +46 (0)8-580 065 99.

## **Important Information**

*In the information below, "this press release" refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction's securities law. Decisions regarding the Merger shall be made solely on the basis of information stated in the merger document relating to the Merger, and to independent*

analyses of the information therein. You should read the merger document that is available on Magle Group's and Amniotics' websites: [www.maglegroup.com](http://www.maglegroup.com) and [www.amniotics.com](http://www.amniotics.com), to obtain more complete information on the Merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision.

*This press release contains forward-looking information. Forward-looking information is inherently associated with known and unknown risks, uncertainties, assumptions and other factors, as it relates to circumstances and depends on circumstances that occur in the future, whether within or outside the respective companies or New Magle Group' control. Such factors may cause actual results, performance and actual development to deviate significantly from what is expressed or implied in the forward-looking information. Although each company' management believes that their expectations stated in the forward-looking information are reasonable based on such information that is available to them, no guarantee is given that such forward-looking information will prove to be accurate. Undue weight should not be given to forward-looking information. The forward-looking information applies only to the day of this press release and neither Magle Group nor Amniotics undertake any obligation to update the forward-looking information beyond what is required pursuant to applicable law. Magle Group' and Amniotics' past performance does not guarantee, and does not represent, the future performance of the through the Merger created "New Magle Group's" control. Furthermore, Magle Group, Amniotics and their respective subsidiaries, senior executives, employees and agents undertake no obligation to review, update or confirm expectations or estimates, or revise forward-looking information to reflect events that occur, or circumstances that arise, in relation to the content of the press release. Furthermore, it is not certain that the Merger will be carried out in the manner and within the time frame described in this press release or at all.*

## Attachments

---

[Magle Group publishes merger document regarding the merger with Amniotics](#)